Sodium Benzoate and Sodium Phenylacetate: Intravenous Nitrogen-Scavenging Agents
Sodium benzoate and sodium phenylacetate are intravenous nitrogen-scavenging medications that provide alternative pathways for waste nitrogen excretion in patients with urea cycle disorders who cannot adequately eliminate ammonia through normal ureagenesis. 1
Mechanism of Action
These agents work by conjugating with amino acids to create excretable compounds that bypass the defective urea cycle:
Sodium Phenylacetate
- Conjugates with glutamine in the liver and kidneys via acetylation to form phenylacetylglutamine 1
- Phenylacetylglutamine is excreted by the kidneys through glomerular filtration and tubular secretion
- Removes 2 moles of nitrogen per mole of phenylacetate (identical nitrogen content to urea) 1
Sodium Benzoate
- Conjugates with glycine (preceded by acylation) to form hippuric acid 1
- Hippuric acid is rapidly excreted by the kidneys via glomerular filtration and tubular secretion
- Removes 1 mole of nitrogen per mole of benzoate 1
The formation of hippurate from benzoate occurs more rapidly than phenylacetylglutamine formation from phenylacetate, and hippurate elimination is faster 1
Clinical Indications
FDA-approved as adjunctive therapy for acute hyperammonemia and associated encephalopathy in pediatric and adult patients with urea cycle enzyme deficiencies 1. These disorders include deficiencies in:
- N-acetylglutamate synthetase (NAGS)
- Carbamyl phosphate synthetase (CPS)
- Argininosuccinate synthetase (ASS)
- Ornithine transcarbamylase (OTC)
- Argininosuccinate lyase (ASL)
- Arginase (ARG) 1
Dosing Protocol
According to consensus guidelines 2:
For patients <20 kg body weight:
- 250 mg/kg of each agent (sodium benzoate AND sodium phenylacetate)
- Given over 90-120 minutes as bolus, then maintenance over 24 hours
For patients >20 kg body weight:
- 5.5 g/m² of each agent
- Given over 90-120 minutes as bolus, then maintenance over 24 hours
Maximum sodium benzoate dose: 12 g daily (high-dose benzoate can be toxic and lethal within 1 hour) 2
Critical Timing Advantage
Intravenous sodium benzoate and sodium phenylacetate can often be administered much more rapidly than kidney replacement therapy (KRT), making them first-line pharmacologic interventions 2. They should be initiated at ammonia levels >150 μmol/l (255 μg/dl) 2
Use with Dialysis
These agents can be administered in conjunction with KRT, though they will be dialyzed along with other small molecules 2. Despite rapid clearance during dialysis, case reports demonstrate successful hyperammonemia correction when nitrogen scavengers are used as a "cocktail" followed by sequential hemodialysis and hemofiltration 2
Pharmacokinetics
Both agents exhibit nonlinear kinetics with decreasing clearance at higher doses 1:
- Phenylacetate remains detectable longer in plasma (Tmax ~2 hours at 3.75 g/m²)
- Benzoate concentrations decline rapidly (Tmax ~1.5 hours at 3.75 g/m²) and become undetectable at 14-26 hours depending on dose 1
Clinical Efficacy
In a 25-year study of 299 patients with 1,181 hyperammonemic episodes 3:
- Overall survival: 84%
- Episode survival: 96%
- Patients >30 days old had better survival than neonates (98% vs 73%, p<0.001)
- 81% of comatose patients survived
- Neonates with peak ammonia >1,000 μmol/l had poorest outcomes (38% survival)
Critical Safety Considerations
Toxicity Risk
Overdosage has resulted in deaths 1. In 16 of 64 deaths in one study, patients received known overdoses. Signs of intoxication include:
- Obtundation (even without hyperammonemia)
- Hyperventilation
- Severe compensated metabolic acidosis with large anion gap
- Hypernatremia and hyperosmolarity
- Progressive encephalopathy
- Cardiovascular collapse 1
Three reported cases of inappropriate dosing resulted in severe complications including cerebral edema, hypotension, and death 4. Ambiguous prescriptions and inadequate cross-checking were the main causes.
Management of Overdose
- Discontinue immediately
- Hemodialysis is the procedure of choice (peritoneal dialysis if hemodialysis unavailable) 1
Limitations
Despite widespread use, no overall superiority among nitrogen scavenging agents has been demonstrated regarding metabolic stability, linear growth, or neurocognitive outcomes 5. Patients remain at risk for:
- Progressive linear growth impairment
- Recurrent annual hyperammonemic events
- Unfavorable neurocognitive outcomes
Current treatments target nitrogenous waste products rather than ammonia directly, highlighting the need for improved therapies 6
Integration with Overall Management
These agents must be combined with 2:
- Temporary cessation of protein intake
- High-calorie IV glucose (8-10 mg/kg/min) and lipids (0.5-3 g/kg daily) to prevent catabolism
- Urea cycle intermediates (L-arginine or L-citrulline) based on specific enzyme deficiency
- Protein reintroduction within 48 hours once ammonia levels reach 80-100 μmol/l to avoid catabolism 2